arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Aspira Women's Health Inc.

AWHL
— Price unavailable
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
67 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
51
Health
Fair
Moderately Bullish
auto_awesome

Analytical Summary

Aspira Women's Health Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap —
Dividend Yield —
Revenue Growth -14.9% ↘
Op. Margin -89.7% ↗
ROIC 23.8% ↘
FCF / Share $-0.05 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -0.23
info Valuation on last close.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.05M
↓ -14.9% —
Net Income Profit after all expenses
$676.00K
— 0.0% —
Operating Margin Operating profit as % of sales
-89.7%
↑ +19.9% 3th
FCF / Share Free cash flow per share
$-0.05
↓ -450.3% —
Long-Term Debt Long-term obligations
$1.16M
↓ -4.8% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
3
Returns
100
Financial Health ↑
55
Cash Quality ↓
42

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 17 years · 67 quarters